XOMA Royalty (NASDAQ:XOMA) Reaches New 52-Week High – Still a Buy?

XOMA Royalty Corporation (NASDAQ:XOMA)’s stock price hit a new 52-week high on Wednesday . The company traded as high as $44.01 and last traded at $43.89, with a volume of 144744 shares trading hands. The stock had previously closed at $43.85.

Analyst Upgrades and Downgrades

XOMA has been the subject of several recent analyst reports. Weiss Ratings upgraded XOMA Royalty from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, May 29th. Lucid Cap Mkts lowered shares of XOMA Royalty from a “strong-buy” rating to a “hold” rating in a report on Monday, April 27th. Benchmark cut shares of XOMA Royalty from a “buy” rating to a “hold” rating in a research report on Friday, May 22nd. HC Wainwright downgraded shares of XOMA Royalty from a “buy” rating to a “neutral” rating and set a $39.00 price target for the company. in a report on Thursday, April 30th. Finally, Zacks Research upgraded shares of XOMA Royalty from a “strong sell” rating to a “hold” rating in a research report on Wednesday, April 8th. One analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, XOMA Royalty currently has a consensus rating of “Hold” and an average target price of $53.75.

XOMA Royalty Trading Down 0.4%

The company’s 50-day moving average is $42.07 and its 200-day moving average is $33.60. The firm has a market cap of $561.79 million, a price-to-earnings ratio of 28.54 and a beta of 0.86. The company has a debt-to-equity ratio of 0.96, a quick ratio of 3.59 and a current ratio of 3.59.

XOMA Royalty (NASDAQ:XOMA) last issued its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.02). XOMA Royalty had a return on equity of 12.56% and a net margin of 53.46%.The company had revenue of $12.32 million for the quarter, compared to the consensus estimate of $13.91 million. On average, research analysts predict that XOMA Royalty Corporation will post 0.9 earnings per share for the current year.

Institutional Trading of XOMA Royalty

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its position in XOMA Royalty by 207.7% in the 1st quarter. Dimensional Fund Advisors LP now owns 133,360 shares of the biotechnology company’s stock worth $4,182,000 after purchasing an additional 90,025 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of XOMA Royalty by 9.7% in the 1st quarter. Bank of New York Mellon Corp now owns 74,984 shares of the biotechnology company’s stock valued at $2,352,000 after buying an additional 6,600 shares during the period. Opaleye Management Inc. raised its position in shares of XOMA Royalty by 14.7% during the fourth quarter. Opaleye Management Inc. now owns 292,590 shares of the biotechnology company’s stock worth $7,780,000 after acquiring an additional 37,503 shares during the last quarter. Squarepoint Ops LLC bought a new stake in shares of XOMA Royalty during the fourth quarter worth $237,000. Finally, Panagora Asset Management Inc. lifted its stake in shares of XOMA Royalty by 24.2% during the fourth quarter. Panagora Asset Management Inc. now owns 21,229 shares of the biotechnology company’s stock valued at $564,000 after acquiring an additional 4,135 shares during the period. Institutional investors and hedge funds own 95.92% of the company’s stock.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.